True excitement is an out of the blue product announcement that’s ready to ship today📦
Do that and everyone will be talking about you and hopefully w revenue recognition
I get that it’s complicated with pipelines, budgeting ans forecasting. Will post about this another time 🐄
If it’s just about iterative improvements (same base tech), then that’s safer. But these can be unexciting and not the point of unveiling the roadmap ⚡️
Big companies know they can’t create the best innovations ❌
Startups do this👍
Most startups fail
The ones that succeed, those in the right place and right time, rarely have the capability to scale on their success
✅Big companies know how to build structures that do this
🐄
It’s attractive to work in startups because of the mindset and growth potential
But there are reasons to work for big companies first:
✅Learn finance metrics
Go beyond revenue, volume, pipelines
✅Learn longer term planning
Plans rarely work out but the exercises are useful
✅Build a global network of colleagues and customers
Useful throughout your career
✅Get to make multiple bets on technologies
Not just survive on the one of your startup
Most importantly:
- Assume AI/ML is at work, when it was just large sample numbers, controlled collection of metadata, and stats
- Assume AI/ML will fix the above if you can achieve that
- Assume collecting data is a viable business model
- Determine what researchers want is what products offer
🐄
Lazy and very poor approaches to analyze genomics markets
- Conflate fundraising with customer demand
- Assume price drives volume
- Assume small companies with exciting announcements serve the market. (Follow Illumina, Danaher, Thermo, less GenomeWeb)
@BrantBassamPhD I’m generally for sequencing approaches as you know but will validate that Illumina had been trying a visium-like approach some ten years back. Unsuccessfully…
Illuminati CEO Jacob Thaysen visiting China with the president’s delegation
Illumina needs population health programs, and China has the biobanks it needs to get into.
Some thorts. . .
🧵
@jmdubs6@OmicsOmicsBlog@plasmidsaurus “MoviePass economics” happening right here! 🐮
(That said I think the company funded this themselves, though the outcome is still the same)
Illumina needs China to give it the relationship from 15 years ago, especially now that it has so much more to offer than just sequencing
GL Jacob! 🫡
🐄
As Illumina goes from just selling genotyping and bulk RNA-seq, it also wants work on methylation, longer reads (whatever we call it these days), proteomics, and tissue - single cell and spatial
All this needs pop health to unlock the vision and scale